LATe TreatmENT Related Toxicity in Melanoma (LATENT)

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · May 9, 2024

Keywords

ClinConnect Summary

The LATe TreatmENT Related Toxicity in Melanoma (LATENT) trial is studying the long-term side effects that patients with advanced melanoma may experience after receiving immunotherapy treatment. While these treatments have significantly improved survival rates, many patients face ongoing health issues as a result. The researchers aim to collect information from about 400 patients who have been successfully treated with immunotherapy for at least three years. They will look at the types, frequency, and severity of these side effects to better understand how to support long-term survivors.

To be eligible for this study, participants need to be at least 18 years old, have a confirmed diagnosis of melanoma, and have been treated with specific immunotherapy drugs between January 2005 and December 2020. The study is not yet recruiting participants, but if you qualify, you can expect to have your medical records reviewed to help gather important data. By participating, you're contributing to a better understanding of how to manage and improve care for patients dealing with the lasting effects of their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of melanoma
• • Age 18 years or older
• • Treated between January 2005- December 2020 with immune checkpoint inhibitor therapy including either Pembrolizumab, Nivolumab, Ipilimumab or combinations, for advanced melanoma (unresectable stage III or stage IV)
• • Ongoing response to therapy of at least 3 years duration at point of study entry
• Exclusion Criteria:
• • Diagnoses of other concurrent malignancies needing active treatment
• • Received Immune checkpoint inhibitors for non-metastatic melanoma or in the adjuvant setting only.
• • Received other treatments including targeted therapy as the most recent line of treatment or following immunotherapy.
• • Progression of disease on or following immunotherapy